Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier Universitaire Vaudois

About this trial

The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

hypogonadotropic hypogonadism

Kallmann syndrome

adult-onset hypogonadotropic hypogonadism

hypothalamic amenorrhea

Disqualifiers

acute illness/hospitalization

pituitary tumors

iron overload (hemochromatosis)

infiltrative diseases (sarcoidosis)

Trial population

Study participants will be a convenience sample of those patients with reproductive disorders (and their family members), with or without cleft lip/palate, who are interested in participating in this genetic study.

Trial design

Design model

Case-control

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants
are grouped into 2 trial groups
Group A: Patients
Group B: Family members

Trial outcomes

Primary outcomes

1

rare sequence variant(s) in gene(s)

The investigators aim to discover genes associated with reproductive disorders by identifying rare sequence variants (mutations) in patients

Time frame
1 year (ongoing if no variants are identified)

Secondary outcomes

1

functionality of identified rare sequence variants (mutations)

The investigators will use a variety of scientific approaches to assess the functional impact of the identified rare sequence variants (mutations)

Time frame
1 year (following variant identification)
2

mode of inheritance

The investigators will examine family pedigrees and study family members to determine the inheritance patterns (how the disorder is transmitted in the family)

Time frame
1 year (following variant identification)
3

genotype-phenotype correlation

The investigators will study the phenotypic spectrum (how the disorder presents clinically) in patients with identified rare sequence variants (mutations)

Time frame
1 year (following variant identification)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire Vaudois

Lead sponsor

Swiss National Science Foundation

Collaborator